Janus Henderson Group PLC Reduces Stock Holdings in Sotera Health (NASDAQ:SHC)

Janus Henderson Group PLC decreased its position in shares of Sotera Health (NASDAQ:SHC - Free Report) by 38.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,782,562 shares of the company's stock after selling 4,886,228 shares during the period. Janus Henderson Group PLC owned approximately 2.75% of Sotera Health worth $106,464,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Barclays PLC increased its stake in Sotera Health by 169.8% in the 3rd quarter. Barclays PLC now owns 473,597 shares of the company's stock worth $7,909,000 after buying an additional 298,085 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Sotera Health by 37.5% in the fourth quarter. GAMMA Investing LLC now owns 4,109 shares of the company's stock valued at $56,000 after purchasing an additional 1,121 shares during the period. Wealth Enhancement Advisory Services LLC grew its stake in Sotera Health by 2.1% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 51,940 shares of the company's stock worth $711,000 after purchasing an additional 1,047 shares in the last quarter. Oak Thistle LLC purchased a new position in Sotera Health during the 4th quarter worth $222,000. Finally, SG Americas Securities LLC raised its position in Sotera Health by 271.6% during the 4th quarter. SG Americas Securities LLC now owns 36,364 shares of the company's stock valued at $497,000 after purchasing an additional 26,577 shares in the last quarter. Institutional investors own 91.03% of the company's stock.

Analyst Ratings Changes

SHC has been the topic of a number of recent research reports. Piper Sandler dropped their price target on Sotera Health from $15.00 to $13.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 23rd. Barclays dropped their target price on shares of Sotera Health from $16.00 to $12.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. Finally, The Goldman Sachs Group raised shares of Sotera Health from a "neutral" rating to a "buy" rating and upped their price target for the stock from $14.00 to $17.00 in a research report on Monday, May 5th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $15.80.

Sotera Health Stock Performance

Shares of NASDAQ SHC traded up $0.06 during midday trading on Friday, reaching $12.80. 948,002 shares of the stock were exchanged, compared to its average volume of 1,198,911. The firm has a 50-day simple moving average of $11.54 and a two-hundred day simple moving average of $12.88. The firm has a market cap of $3.63 billion, a price-to-earnings ratio of 51.20 and a beta of 1.88. Sotera Health has a twelve month low of $9.53 and a twelve month high of $17.08. The company has a quick ratio of 2.61, a current ratio of 2.88 and a debt-to-equity ratio of 4.91.

Sotera Health (NASDAQ:SHC - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported $0.14 EPS for the quarter, beating analysts' consensus estimates of $0.12 by $0.02. The company had revenue of $254.52 million during the quarter, compared to the consensus estimate of $245.56 million. Sotera Health had a net margin of 6.31% and a return on equity of 42.27%. Sotera Health's quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.13 EPS. As a group, analysts anticipate that Sotera Health will post 0.61 EPS for the current fiscal year.

Sotera Health Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.